Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Tekmira Pharmaceuticals — Merger or Acquisition (February 2015)
16 slides from Arbutus Biopharma's merger presentation, Feb 11, 2015
Slide 1: Creating a Leading Global HBV Therapeutics Company
Creating a Leading Global HBV Therapeutics Company Tekmira
Slide 2: Forward Looking Statements
Slide 3: Chronic HBV — greatest global unmet medical need
Chronic HBV — greatest global unmet medical need @ Chronic HBV Infections @ HBV Genotypes (A-H)
Slide 4: Our Goal - an all oral, curative therapy for HBV
Our Goal - an all oral, curative therapy for HBV + HBV biology is complex — More complex than HCV + HBV persists by 1. Replicating continually in liver hepatocytes 2. Expressing viral antigens that suppress the patients’ immune response 3. Establishing a stable cccDNA reservoir in the nucleus * Cura
Slide 5: Our Strategy — all needed assets under one roof
Our Strategy — all needed assets under one roof * Provide a cure by developing combination therapies acting by complementary mechanisms of action against the virus — Aggressively suppress viral replication — Reactivate/stimulate the immune system — Eliminate cccDNA * Considered the “Holy Grail” in a
Slide 6: Transaction Highlights
Transaction Highlights * Combined company well positioned to capitalize on the global market opportunity in HBV and create significant long-term value for shareholders + Creates the industry's leading portfolio of therapeutic approaches to cure HBV, addressing a significant unmet medical need + Eigh
Slide 7: Proven Leadership
Proven Leadership + Mark Murray, Chief Executive Officer (Tekmira) + Patrick Higgins, President and Chief Operating Officer (OnCore, former Pharmasset) + Bruce Cousins, Chief Financial Officer (Tekmira) + Michael Sofia, Chief Scientific Officer (OnCore, former Pharmasset) + William Symonds, Chief De
Slide 8: Building the "HBV Solutions" Company
Building the “HBV Solutions’ Company Hepatitis B is a bigger market than Hepatitis C Building a portfolio of HBV assets that will lead to curative therapy Differentiating from the potential competition in multiple ways: 1. Utilization of combination therapy with a three-pillar approach 2. Nine compo
Slide 9: OnCore-Tekmira Development Pipeline
OnCore-Tekmira Development Pipeline Adresse HBV Persistent tage of erkpmont Immune cccDNA Preclinical ev Systm Formation Candidate! Replication Stimulation’ Inhibition’ Leac IND a ibon Rescvaton Elmintion Resch Opinion Ewing Phase _—_Canat/ Pogam Tas e [aaa = cca.n0 Ce cinta) e.°e a) Leese omnewoVin
Slide 10: TKM-HBV: Targeting Multiple HBV Transcripts
TKM-HBV: Targeting Multiple HBV Transcripts + Design an anti-HBV RNAi Trigger ‘payload’ that is: — Potent - reduces viral protein production, especially HBsAg — Universal - effective against all genotypes All three triggers target the 2.1/2.4 kb sAg encoding mRNAs and also cleave 3.5 kb and 0.7 kb m
Slide 11: Relationship with Baruch S. Blumberg Institute
Relationship with Baruch S. Blumberg Institute Blumberg Institute is One of the Leading Research Institutes Focused on HBV + License Agreements with Blumberg and Drexel University +» Research Funding and Collaboration Agreement with (Drexel) — February 2014 and November 2014 ah + Patent License Agre
Slide 12: Combination Development Strategy Driven by the ELECTRON engine
Combination Development Strategy Driven by the “ELECTRON engine” Phase 4/2 Proof of Activity BRR Will initially combine with existing NUC therapy J
Slide 13: Advancing Non-HBV Programs
Advancing Non-HBV Programs Focus _ Indication Product Research ical Phase! Phasell Pha: Gastrointestinal Neuroendocrine Tumors TKM-PLK1: GI-NET Adrenocortical Carcinoma TKM-PLK1: ACC. Hepatocellular Carcinoma TKM-PLK1: HCC Ebola Virus Infection TKM-Ebola Ebola Virus Infection TKM-Ebola-Guinea Marbur
Slide 14: OnCore-Tekmira Transaction Details
OnCore-Tekmira Transaction Details * OnCore will become a wholly-owned subsidiary of Tekmira + Merger of equals as determined by the treasury stock method + Implied market value of the combined company, based on the closing price of Tekmira common shares on the NASDAQ Global Market on January 9, 201
Slide 15: Conclusion
Conclusion * Combined company well positioned to capitalize on the global market opportunity in HBV and create significant long-term value for shareholders * Creates the industry’s leading portfolio of therapeutic approaches to cure HBV, addressing a significant unmet medical need + 8 unique drug ca
Slide 16: Creating a Leading Global HBV Therapeutics Company
Creating a Leading Global HBV Therapeutics Company Tekmira
Tekmira Pharmaceuticals — Merger or Acquisition (February 2015) on 6ix